An Update for the Haemophilia Community on HEMLIBRA® (emicizumab)

On 1 February 2019 a U.S. district court issued a final judgment in favour of Genentech and against Shire, through its wholly-owned subsidiaries Baxalta Inc. and Baxalta GmbH. The judgment states that HEMLIBRA does not infringe Shire’s patent (U.S. Patent, 7,033,590) based on the court’s definition of key terms related to the patent. This follows the court’s ruling in August 2018 denying the request from Shire for a preliminary injunction that intended to prevent certain patients in the U.S. from receiving HEMLIBRA. Since the case has been resolved in favour of Genentech, there is no longer a trial scheduled for September 2019.

This outcome protects the rights of people with haemophilia A, their families and doctors to decide if HEMLIBRA is the right medicine for them. We are confident that patient access to HEMLIBRA in the U.S. will not be affected as a result of this legal matter.

At the Roche Group—Genentech in the U.S., Chugai in Japan, and Roche in the rest of the world—we look forward to continuing to focus on the haemophilia community and making HEMLIBRA available to people all over the world who are living with haemophilia A and may benefit from this therapy.